4 recruiting, 1 completed. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Gram Negative Infections: new trials by email Literature Review of Gram Negative Infections trials Research Report on Gram Negative Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients Clinical Stability-Driven Antibiotic Discontinuation Strategy, Standard of Care Antibiotic Duration - Bloodstream Infection, Gram Negative Infections | Not applicable | Recruiting | Valeria Cento | 172 | 2026-02-02 | 2026-09-24 |
| A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections Ceftazidime± avibactam with fosfomycin, Ceftazidime± avibactam with placebo - Gram Negative Infections, Sepsis and Septic Shock | Phase 3 | Recruiting | Angela HUTTNER | 100 | 2025-08-25 | 2025-09-26 |
| A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections Meropenem plus vaborbactam - Gram Negative Infections | Phase 2 | Recruiting | Menarini Group | 44 | 2025-02-18 | 2026-10-07 |
| PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE Gram Negative Infections, Antimicrobial Resistance (AMR) | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 60 | 2023-12-01 | 2026-06-12 | |
| Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections Ceftazidime-avibactam - Gram Negative Infections | Completed | Pfizer | 189 | 2021-01-29 | 2024-08-14 |
Sepsis (2) · Febrile Neutropenia (1) · Shock, Septic (1)
Infections (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Systemic Inflammatory Response Syndrome (2) · Agranulocytosis (1) · Cytopenia (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukocyte Disorders (1) · Leukopenia (1) · Neutropenia (1) · Shock (1)
avibactam, ceftazidime drug combination (2) · Fosfomycin (1) · Meropenem (1) · vaborbactam (1)
Angela HUTTNER (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Menarini Group (1) · Pfizer (1) · Valeria Cento (1)
Italy (3) · Spain (2) · Czechia (1) · France (1) · India (1) · Poland (1) · Switzerland (1)
Maddalena Giannella, MD PhD (1) · Valeria Cento, MD, PhD (1)